Overview

Canadian Blood Services has announced that in response to a heightened risk environment, it is taking action to increase and protect the supply of plasma for immunoglobulins in Canada. To that end, we are releasing a comprehensive risk analysis that provided five recommendations for collaborative action across the broader blood supply system, including recommendations to act with urgency and to leverage both not-for-profit and commercial sectors. We are also announcing a related agreement with Grifols, a global healthcare company and leader in producing plasma medicines.

Our priority is to ensure lifesaving immunoglobulins remain available for patients in Canada. Under the agreement, to reach a minimum target of 50 per cent sufficiency in the quickest time possible, both Canadian Blood Services and Grifols will collect plasma which will be made into immunoglobulins for patients in Canada. Canadian Blood Services will purchase these finished medications from Grifols. Purchasing medications from the commercial plasma sector as been part of our practice for more than two decades.

The agreement will:

- Provide essential protections for the national blood system, including controls to prevent negative impacts on Canadian Blood Services’ current and future network of blood and plasma donor centres;
- Ensure plasma donated in Canada is used to make medications in Canada exclusively for patients in Canada; and,
- Enable the country’s first end-to-end supply chain to meet patients’ critical needs for immunoglobulins — many of whom have no other treatment option available.

The agreement does not involve the sale of any aspect of the national blood supply system and in no way changes Canadian Blood Services’ previously announced plans to collect more plasma. Canadian Blood Services will continue to increase the number of plasma donor centres it operates across the country.

These are responsible actions for the blood operator to take, in the best interest of patients, and in keeping with our mandate to ensure security of supply of needed blood and plasma products for the country.

The material below provides essential background on the environment informing these actions, the risk analysis and the agreement with Grifols.
Key Facts

- Plasma is a straw-coloured liquid that makes up most (55 per cent) of the body’s blood volume. It is rich in proteins that protect the body from illness, infection and excessive bleeding.

- Immunoglobulins are the most widely used type of medications made from plasma. They are used to treat patients with primary and secondary immunodeficiency disorders, autoimmune disorders and neurological disorders, along with other medical conditions.

- Canadian Blood Services estimates that more than half (50–60 per cent) of patients in Canada prescribed immunoglobulins must use them to live, with no other treatment option available for care.

- Canadian Blood Services is Canada’s national blood operator (except Québec). As such, Canadian Blood Services is accountable for managing the integrated national blood system on behalf of provincial and territorial governments, including the supply of plasma and plasma-derived medications, such as immunoglobulins.

- Domestic sufficiency is the percentage of a country’s total need for immunoglobulins that is met with plasma collected within that country.

- Currently, Canadian Blood Services collects enough plasma to manufacture 15 per cent of the immunoglobulins needed in Canada. The balance (~85 per cent) of immunoglobulins is purchased from the global biologics industry through competitive procurement processes and made from plasma collected by other sources (including paid donors).

- A plasma sufficiency target of 50 per cent was established in 2016 through a risk-based decision-making analysis to ensure patients’ critical needs in Canada will continue to be met into the future.

- The risk analysis was repeated in 2021–2022. It confirmed this target remains appropriate, and that in Canada (excluding Québec), an estimated 50-60 per cent of immunoglobulins are used to treat life-threatening medical conditions for which no other therapy is available.

- Because demand for immunoglobulins is outpacing the plasma collections necessary to make them, there is currently a global shortage of immunoglobulins.

- The COVID-19 pandemic has further disrupted global supply chains for many essential products including plasma-derived medications, and escalated supply and demand pressures.

- In response, with governments’ support, Canadian Blood Services continues to open new plasma donor centres and maximize its plasma collection capacity. Once fully operational, these activities will increase domestic plasma sufficiency to approximately 25 per cent.

- While we are moving in the right direction, there remains a significant gap to meet a minimum 50 per cent target urgently, to secure supply for patients who use the product on a lifesaving basis.
To help inform the risk analysis, Canadian Blood Services also conducted a transparent and comprehensive request for proposal (RFP) process to assess whether the commercial plasma sector could be leveraged while still maintaining protections for the national supply chain.

Grifols was the successful proponent. We have announced an agreement with Grifols that will enable an end-to-end domestic supply chain, while achieving essential protections for the national blood system.

Under this agreement, both Canadian Blood Services and Grifols will collect plasma in Canada toward a sufficiency target of 50 per cent. This plasma will be made into immunoglobulins for patients in Canada.

Outside of this agreement, plasma collected by the commercial plasma industry, does not contribute to Canada’s plasma sufficiency. Rather, this plasma is made into medications that are sold on the global market for patients around the world, with no guarantee it will stay in Canada to help patients here.

To be clear, Canadian Blood Services is not purchasing plasma in this agreement. Rather, we are purchasing finished medications, which has been our practice for more than two decades.

Environment/Context

Constricted global supply: Use of immunoglobulins has been growing in health systems around the world for many years. Blood supply systems and the global commercial plasma sector are not currently able to collect enough plasma to meet demand.

In August of 2019, the American Food and Drug Administration declared a shortage of immunoglobulins that continues to affect patients today. The U.S. supplies much of the world with plasma for plasma protein products, but despite the large amount of plasma collected in the U.S., there continues to be inadequate plasma to meet global need for immunoglobulins. This is why many countries are seeking to increase plasma collection to keep up with growing demand.

This shortage has been made more acute by the COVID-19 pandemic, which has disrupted supply chains internationally. The pandemic has caused countries to try to ensure that more vital medical therapies, such as vaccines and other products, are manufactured domestically.

Canadian Blood Services and plasma sufficiency: Part of Canadian Blood Services’ role is maintaining Canada’s plasma sufficiency to make immunoglobulins and other plasma-derived medications for use by hospitals and patients across the country. Key to this is regular monitoring of supply and demand to identify emerging risks and enable an appropriate, effective response.

Canadian Blood Services ensures security of supply for immunoglobulins by doing two things:
1. Collecting plasma we ship to pharmaceutical companies in the global biologics industry that manufacture medications, including immunoglobulins, on our behalf and exclusively for use in Canada. The medications are then licensed by Health Canada and returned to Canadian Blood Services for supply to the health centres we serve.

2. Bulk purchasing additional medications, including immunoglobulins, which are manufactured by the global biologics industry using plasma they have collected themselves. We supply these and other related products which we have also purchased on the global market, to provincial and territorial health systems to ensure patients’ needs are met in Canada.

These two activities meet 100 per cent of demand immunoglobulins in Canada (excluding Quebec).

**Why we must increase plasma sufficiency for immunoglobulins in Canada:** Currently, Canadian Blood Services collects about 15 per cent of the plasma required to manufacture immunoglobulins for health centres we serve. This does not mean patients are going without treatment. Rather, it means that we purchase the balance (approximately 85 per cent) of the immunoglobulins as finished medications from the global biologics industry, which are made from plasma they collected themselves.

Because demand for immunoglobulins is outpacing plasma collections necessary to make them, there is currently a global shortage of immunoglobulins. It essential for blood supply systems around the world to increase their plasma collection substantially, including here in Canada.

In recent years, third-party reports have validated the need to collect more plasma in Canada:

- The 2018 Health Canada Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada recommended options “be carefully examined to ensure that all source plasma collected in Canada from Canadian donors (whether paid or volunteer) be made available for the needs of Canadian patients”.

- The 2020 Ontario Auditor General audit related to blood and blood products recommended Canada achieve 50 per cent immunoglobulin sufficiency as soon as possible.

**How Canadian Blood Services is growing Canada’s plasma supply:** With financial support from federal, provincial and territorial governments, Canadian Blood Services is growing its capacity to collect more plasma. Since 2020, we have opened five dedicated plasma donor centres in Kelowna, B.C.; Lethbridge, Alta.; and, in Ontario, Brampton, Ottawa and Sudbury; with three more centres planned for spring 2023 in Abbotsford, B.C., and in St. Catharines and Vaughan, Ont. Pending confirmation of financial support, another three centres will follow to bring the total to 11 dedicated plasma donor centres in Canada in 2024. We are also improving pre-existing plasma collection programs at our blood donor centres. Together, these enhancements are expected to achieve approximately 25 per cent plasma sufficiency once the centres are fully operational.
While these efforts will improve plasma sufficiency in Canada, there remains a significant gap to meet a minimum target of 50 per cent sufficiency urgently, to bring greater security to the supply of immunoglobulins for patients in Canada who use them on a lifesaving basis.

Risk Analysis

In 2021–2022, Canadian Blood Services applied the Alliance of Blood Operator’s Risk-Based Decision-Making framework to refresh similar work conducted in 2016–2017 and to assess ongoing and emerging risks to plasma and immunoglobulin supplies. This framework was developed to facilitate blood-system decision-making in complex situations and is a best practice used by blood operators around the world.

The analysis included substantive input from experts and stakeholders, including governments, patients, clinicians, industry and market analysts, health economists, ethicists, legal specialists and international blood operators, among others. It includes qualitative and quantitative assessments, including horizon scans on supply and demand for immunoglobulins, reviews of emerging alternative treatments, jurisdictional scans, and a health economics study. It was also informed by stakeholder consultations.

Through the analysis, the following five key recommendations were generated, which provide a blueprint for collaborative action across the broader blood system to bring greater security to the supply of immunoglobulins in Canada:

1. Undertake additional risk-mitigation measures with urgency
2. Pursue a targeted range of approximately 50–60 per cent domestic plasma sufficiency to meet patients’ most critical needs in Canada — which have no other treatment option.
3. Leverage both not-for-profit and commercial sectors
4. Continue working with the National Emergency Blood Management Committee, a pan-Canadian expert advisory body, to address short-term product shortages
5. Maintain active monitoring of supply and demand for immunoglobulins

The report from the analysis was completed and shared with governments in June 2022. Some of these recommendations are already in various stages of implementation by Canadian Blood Services and governments.

A role for the commercial plasma sector

To help inform this risk analysis, and in alignment with the recommendations of Health Canada’s expert panel, Canadian Blood Services conducted a transparent and comprehensive RFP process to assess whether the commercial plasma sector could be leveraged while still maintaining protections for the national supply chain. With this caveat, our objectives were to secure a greater domestic supply of immunoglobulins in a timely and cost-effective way and
achieve an end-to-end supply chain for immunoglobulins in Canada. The successful proponent of the request for proposal was Grifols.

Through this agreement, we will be able to:

- Enable an end-to-end domestic supply chain for immunoglobulins where plasma is collected and manufactured in-country exclusively for patients in Canada
- Rapidly increase domestic plasma sufficiency to reach a minimum 50 per cent sufficiency target
- Reach the optimal sufficiency target at a competitive price
- Offer greater predictability of cost than purchasing immunoglobulins from the global market and remove foreign exchange and high demand volatility
- Ensure that Grifols does not operate in direct competition with Canadian Blood Services’ existing blood and plasma collection network built through investments by governments and that they only collect the amount of plasma required to fulfill the needs of Canadian Blood Services

To be clear, Canadian Blood Services is not purchasing plasma in this agreement. Rather, we are purchasing finished medications, which has been our practice for more than two decades.

The difference, under this agreement, is that immunoglobulins purchased from Grifols will be made from plasma collected in Canada and manufactured in Canada, enabling the country’s first end-to-end domestic supply chain for immunoglobulins.

The agreement includes important measures to prevent negative impacts on Canadian Blood Services’ plasma and blood collections, as well as clear benefits in terms of stable pricing of these medications for provinces and territories. It also includes measures to prevent plasma collected and manufactured by Grifols in Canada from being sold or shipped offshore, ensuring plasma collected in Canada benefits patients in Canada. (See below for details.)

It is important to recognize that this agreement represents only part of the recommendations put forward by the risk analysis. Canadian Blood Services will also continue to expand its own plasma collections network across the country. Further, we are engaged in a range of other system-level activities designed to mitigate risk to security of supply of plasma for immunoglobulins.

Key points of the agreement:
• **Preventing negative impacts on Canadian Blood Services’ blood and plasma network:** The agreement provides Canadian Blood Services the right to approve the location of Grifols’ sites. Grifols cannot operate plasma collection sites outside the agreement in Canada (i.e., all plasma collected by Grifols in the country will contribute to Canadian Blood Services’ plasma sufficiency for immunoglobulins).

• **Plasma collected in Canada stays in Canada for patient care:** Grifols cannot ship or sell plasma they collect in Canada to other countries (i.e., all plasma collected by Grifols in Canada will be used to manufacture immunoglobulins on behalf of health systems in Canada via Canadian Blood Services, exclusively for patient care in Canada).

• **Operational independence:** Canadian Blood Services and Grifols operations will remain separate and autonomous; however Grifols’ consent forms will note that the plasma they collect will be used to make products for Canadian Blood Services to meet the needs of Canadian patients. Operational independence also means that Canadian Blood Services is not prohibited from purchasing finished products from other vendors, as it currently does now, on the global market or sending plasma Canadian Blood Services collects to other fractionators, to ensure essential diversification of supply.

• **Cost competitiveness:** Canadian Blood Services remains committed to delivering an adequate supply of immunoglobulins for patients in Canada at an affordable cost to Canadian health-care systems. Immunoglobulins acquired through this agreement will be purchased at a competitive rate to the international market, particularly in the context of the tightening global supply.

**Canadian Blood Services’ long-standing relationship with Grifols**

Canadian Blood Services and the broader transfusion community in Canada have had a long and positive relationship with Grifols, a global healthcare company and leader in producing plasma medicines. The company has gained deep knowledge of Canada’s plasma and health-care systems over the more than 30 years it has manufactured plasma collected in Canada at its facilities in the U.S. These contract manufacturing services have enabled Grifols to provide plasma-derived medications that have enhanced the lives of thousands of patients in Canada for decades.

In 2020, Grifols purchased manufacturing facilities in Montréal, with the intention of being fully operational sometime in 2026. Grifols will begin producing immunoglobulins and other plasma medications manufactured from Canadian plasma, in Montréal sometime in 2026. This manufacturing capacity in Canada will provide an essential component in the domestic end-to-end supply chain which will reduce risk to Canada’s supply of immunoglobulins by providing a manufacturing facility within the country. The company also owns a plasma collection site in Winnipeg.
Commercial plasma sector in Canada

Commercial plasma collection (where donors are remunerated) is a relatively new dynamic in Canada. We have always maintained that a small number of commercial collection sites would not have a negative effect on the national blood system supply chain. However, large-scale commercial growth — without appropriate controls — could have negative impacts on the existing system for both blood and plasma collections and threaten our ability to meet patient need. At the same time, Canadian Blood Services recognizes that governments continue to hold a range of views about commercial plasma collection. All governments agree, however, that Canada must increase plasma collection and immunoglobulin sufficiency with some urgency.

This agreement solves these challenges by ensuring necessary domestic security of supply, with both Canadian Blood Services and Grifols collecting more plasma on behalf of Canadians and manufacturing that plasma on Canadian soil. It also provides essential protections from negative impacts of large commercial industry on national blood system operations, something we realized was not achievable legislatively in a timely manner across all jurisdictions where we operate.

Looking ahead

Canadian Blood Services will continue discussions with governments to determine how, as a country, we should approach commercial plasma collection with respect to sufficiency needs and to further mitigate any impact on national blood supply system operations and our mandate to provide these lifesaving products to hospitals for patients in Canada. Our agreement with Grifols does not negate the need for these ongoing discussions.

Canadian Blood Services continues to manage the blood and plasma supply system in all provinces and territories except Québec. This agreement with Grifols does not encroach upon or minimize our role. We will continue to ensure the supply of blood and plasma products for patients across the country.

Canadian Blood Services has no plans to remunerate donors. We will continue to collect plasma and blood, and to encourage registration for stem cell, organ and tissue donation in the same manner we always have. We do all our work with the overarching and ever-present priority of safety and security of supply for patients. The actions outlined in this document align with this priority and will help us achieve one of our essential objectives: to increase plasma sufficiency on behalf of patients in Canada.